Maxim Group began coverage on shares of BioHarvest Sciences (NASDAQ:BHST - Free Report) in a research report report published on Wednesday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $12.00 price objective on the stock.
Separately, HC Wainwright started coverage on BioHarvest Sciences in a research report on Friday, December 6th. They set a "buy" rating and a $14.00 target price on the stock.
View Our Latest Stock Report on BioHarvest Sciences
BioHarvest Sciences Stock Up 0.2 %
BHST stock traded up $0.01 during trading on Wednesday, reaching $6.20. 19,196 shares of the stock were exchanged, compared to its average volume of 3,564. BioHarvest Sciences has a twelve month low of $6.11 and a twelve month high of $7.70. The company has a market cap of $101.84 million and a PE ratio of -4.96.
BioHarvest Sciences Company Profile
(
Get Free Report)
BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.
Featured Stories
Before you consider BioHarvest Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioHarvest Sciences wasn't on the list.
While BioHarvest Sciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
